The HDAC8 Knockout LoVo Polyclonal Cells are a CRISPR/Cas9-edited polyclonal population with targeted disruption of the HDAC8 gene in LoVo human colorectal adenocarcinoma cells. This loss-of-function model enables investigation of HDAC8??s role in cancer-relevant pathways in a native cellular context. The polyclonal format provides a mixture of edited alleles for robust functional studies.
LoVo cells originate from a metastatic colon adenocarcinoma and exhibit microsatellite instability and mutant p53, mirroring common colorectal cancer features. This genetic background is ideal for studying DNA damage responses and epigenetic deregulation. The HDAC8 knockout thus offers a precise system to probe deacetylase-dependent mechanisms within this clinically relevant model.
HDAC8, a class I histone deacetylase, catalyzes deacetylation of histones H3 and H4, leading to chromatin condensation and transcriptional repression. Its activity is modulated by phosphorylation via cAMP-dependent protein kinase (PKA) and by DNA damage signaling cascades. Key non-histone substrates include the tumor suppressor p53, the cohesin subunit SMC3, ??-tubulin, and estrogen receptor ??, through which HDAC8 influences apoptosis, chromosome segregation, and hormone signaling. It forms corepressor complexes with SMRT and NCoR and interacts with HP1 and p53. In cancer, HDAC8 overexpression silences p53, promoting proliferation; conversely, inhibition restores p53 activity and triggers apoptosis.
In the mutant p53 LoVo background, HDAC8 knockout permits dissection of non-histone deacetylation pathways that may bypass canonical p53-dependent apoptosis. This model is particularly useful for studying HDAC8??s impact on cohesin dynamics, MYC-driven proliferation, and hormone receptor signaling, all frequently dysregulated in colorectal cancers with microsatellite instability.
These polyclonal knockout cells are well-suited for diverse functional genomics and drug discovery applications. Transcriptome-wide changes can be assessed by RNA-seq, while locus-specific histone acetylation alterations are detectable by ChIP-qPCR. Flow cytometry enables quantitative analysis of apoptosis and cell cycle distribution, and cell proliferation assays measure growth kinetics. HDAC enzymatic activity assays and drug sensitivity testing facilitate preclinical evaluation of HDAC inhibitors. Standard techniques like Western blotting and RT-qPCR confirm HDAC8 disruption, and immunofluorescence monitors protein localization. Researchers can employ this model to dissect HDAC8-dependent signaling networks and identify novel therapeutic targets. For additional technical details, please contact Ascent Research.
